Sorin Group's Annuloplasty Ring MEMO 3D(TM) Obtained CE Mark; Presented at the 5th EACTS/ESTS the Product Major Features and the First Implant

19/09/2006 - 12:32

Sorin Group (MIL:SRN), Europe's largest medical
technology company specialized in the treatment of cardiovascular
diseases and leader in Cardiac Surgery, presented last week, at the
5th EACTS/ESTS Joint Meeting Congress, the new MEMO 3D(TM) Semirigid
Annuloplasty Ring, which received CE mark approval last August.
Memo 3D(TM) it is the only semirigid annuloplasty ring designed to
mimick the physiological three-dimensional motion of the mitral
annulus. Thanks to a shape memory and superelastic metal alloy
internal core, which allows the ring to adapt to the annular saddle
shape and keep memory, the device can ensure both mitral annulus shape
and function during cardiac cycle.
Memo 3D(TM) is coated with Carbofilm, a carbon coating aimed at
improving haemo and biocompatibility.
This ring is the result of synergies between coronary stent
technology,the ring's laser-cut internal core and valve prostheses
know how.
Prof. Fischlein (Friedrich Alexander University, Erlangen,
Germany) presented the product's major features and first implant
during the Satellite Symposium "Controversial Cases in the Treatment
of Mitral and Tricuspid Valves Diseases" chaired by Dr. Alfieri (San
Raffaele Hospital, Milan).
The satellite symposium, attended by 450 heart surgeons coming
from all over the world, has given Dr. Lessana (Centre Cardiologique
du Nord, Paris, France) and Dr. Mascagni (Villa Maria Cecilia
Hospital, Cotignola, Italy) the opportunity to discuss some
controversial cases on mitral and tricuspid valves disease, with an
interesting real time televoting system, which made the interaction
with the audience fruitful.
"Memo 3D(TM) represents a real break-through in cardiac surgery,
because it is designed to restore the left ventricular function of the
human heart", said Franco Vallana, President, of the Cardiac Surgery
Business Unit.

About MEMO 3D(TM) Annuloplasty Ring

-- Innovative cell-structure design, capable of mimicking the
physiological three-dimensional motility of the native mitral
annulus and accommodating the anatomical saddle shape;

-- Shape memory and super-elastic alloy core, aimed at restoring
the native shape and function;

-- Sorin Group's exclusive Carbofilm(TM) coating for enhanced
haemo- and bio-compatibility;

-- Ease of implant, according to a pre-defined line and thanks to
a particular configuration of the silicon filler.

About Sorin Group

Sorin Group (Reuters code: SORN.MI), a world leader in the
development of medical technologies for cardiac surgery, offers
innovative therapies for cardiac rhythm dysfunctions, interventional
cardiology and the treatment of chronic kidney diseases. The companies
of Sorin Group are: Bellco, CarboMedics, COBE Cardiovascular, Dideco,
ELA Medical, Mitroflow, Soludia, Sorin Biomedica and, Stockert. Sorin
Group has about 4,600 employees working at facilities in more than 80
countries throughout the world to serve over 5,000 public and private
treatment centers.